Humana (HUM) Given New $370.00 Price Target at Credit Suisse Group

Share on StockTwits

Humana (NYSE:HUM) had its target price lifted by Credit Suisse Group from $350.00 to $370.00 in a report released on Tuesday, The Fly reports. They currently have an outperform rating on the insurance provider’s stock.

A number of other research analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Humana from a buy rating to a hold rating in a research report on Wednesday, August 8th. Argus boosted their target price on shares of Humana to $375.00 and gave the stock a buy rating in a research report on Tuesday. ValuEngine downgraded shares of Humana from a buy rating to a hold rating in a research report on Saturday, June 2nd. Citigroup reissued a buy rating and issued a $340.00 target price (up from $280.00) on shares of Humana in a research report on Friday, June 1st. Finally, Piper Jaffray Companies boosted their target price on shares of Humana from $355.00 to $380.00 and gave the stock an overweight rating in a research report on Friday, August 24th. Six analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Humana has a consensus rating of Buy and an average target price of $328.94.

Shares of HUM opened at $337.13 on Tuesday. Humana has a 52 week low of $231.90 and a 52 week high of $337.56. The company has a market cap of $46.00 billion, a P/E ratio of 26.15, a P/E/G ratio of 1.66 and a beta of 0.96. The company has a current ratio of 1.43, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, August 1st. The insurance provider reported $3.96 EPS for the quarter, beating the Zacks’ consensus estimate of $3.79 by $0.17. Humana had a net margin of 2.48% and a return on equity of 17.43%. The firm had revenue of $14.26 billion for the quarter, compared to the consensus estimate of $14.16 billion. During the same period in the previous year, the firm posted $3.49 earnings per share. equities research analysts predict that Humana will post 14.18 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 26th. Shareholders of record on Friday, September 28th will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 0.59%. The ex-dividend date of this dividend is Thursday, September 27th. Humana’s dividend payout ratio is 17.08%.

In related news, insider Elizabeth D. Bierbower sold 3,092 shares of the company’s stock in a transaction on Thursday, August 16th. The shares were sold at an average price of $330.00, for a total transaction of $1,020,360.00. Following the completion of the sale, the insider now directly owns 14,289 shares of the company’s stock, valued at approximately $4,715,370. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Timothy Alan Wheatley sold 11,468 shares of the company’s stock in a transaction on Tuesday, June 19th. The stock was sold at an average price of $299.40, for a total transaction of $3,433,519.20. Following the sale, the insider now directly owns 3,889 shares of the company’s stock, valued at $1,164,366.60. The disclosure for this sale can be found here. Insiders sold 92,431 shares of company stock valued at $28,602,805 over the last three months. Insiders own 0.60% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of HUM. FDx Advisors Inc. boosted its holdings in shares of Humana by 42.7% during the 1st quarter. FDx Advisors Inc. now owns 2,248 shares of the insurance provider’s stock worth $604,000 after buying an additional 673 shares during the period. Commerzbank Aktiengesellschaft FI boosted its holdings in shares of Humana by 338.9% during the 1st quarter. Commerzbank Aktiengesellschaft FI now owns 7,913 shares of the insurance provider’s stock worth $2,127,000 after buying an additional 6,110 shares during the period. Alps Advisors Inc. raised its stake in Humana by 130.4% during the 1st quarter. Alps Advisors Inc. now owns 3,341 shares of the insurance provider’s stock valued at $898,000 after purchasing an additional 1,891 shares during the last quarter. Atria Investments LLC raised its stake in Humana by 8.4% during the 1st quarter. Atria Investments LLC now owns 5,564 shares of the insurance provider’s stock valued at $1,496,000 after purchasing an additional 433 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Humana by 3.0% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 40,052 shares of the insurance provider’s stock valued at $10,767,000 after purchasing an additional 1,148 shares during the last quarter. 93.00% of the stock is owned by institutional investors and hedge funds.

Humana Company Profile

Humana Inc is a health and well-being company focused on making it easy for people to achieve best health. Its strategy integrates care delivery, the member experience, and clinical & consumer insights to encourage engagement, behavior change, proactive clinical outreach, and wellness for the people.

See Also: How Important is Technical Analysis of Stocks

The Fly

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply